BioPharma Resources

Drug Trial Radar · NCT07836660

A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 198 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

198

Planned (sponsor's estimate)

Start

Oct 15, 2026

Primary completion

Nov 1, 2027

Study completion Oct 31, 2028

Sponsor

Sponsor type
Industry
First posted
Sep 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of IBI355 in participants with moderate-to-severe Sj?gren's disease (SjD).

Conditions

  • Sjögren's Disease

Interventions

  • Part A - Placebo for IBI355Drug

    Matching placebo of IBI355, IV ,corresponding dose regimen according to study design

  • Part B -TelitaciceptDrug

    Telitacicept 160 mg SC QW × 24 doses (Weeks 0-24).

  • PartB -Placebo for TelitaciceptDrug

    Matching placebo of Talitacicept ,SC QW × 24 doses.

  • Part A - IBI355Drug

    IBI355,IV,corresponding dose regimen according to study design

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 24Time frame: Baseline and Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of University of Science and Technology of China

    Hefei, Anhui, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.